Pyoderma gangrenosum is an ulcerating disorder of the skin with sterile neutrophilic inflammation that may be seen in up to 5% of patients with chronic ulceration of the legs. 1 Typically painful, it ...

References ↵ Lopez Pineiro M, Willis E, Yao C, et al . Pyoderma gangrenosum-like ulceration of the lower extremity secondary to sunitinib therapy: a case report. SAGE Open Med Case Rep 2018; 6: ...

Vegetative pyoderma gangrenosum: This type, also known as superficial pyoderma gangrenosum, causes ulcers that are not particularly deep or painful. It usually develops in people with no ...

This research is significant as Humira is the only approved treatment for Pyoderma Gangrenosum in Japan. The study tested Humira (Adalimumab), an injectable medication, on approximately 60 ...

“A MID of 7-day pain scores for pyoderma gangrenosum was a 2-point improvement on an NRS,” the authors wrote. “Improvement of 2 or more points in pain may be an indication that a patient is ...

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported orphan drug designation by both US FDA and ...

METHODOLOGY: To help determine whether a patient with pyoderma gangrenosum is responding to treatment, researchers used a patient global assessment (PGA) score to establish a minimal important ...

JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...

Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...